Miotto Edivaldo, Salvatore Freitas Karina Maria, Mori Aline Akemi, Valarelli Fabricio Pinelli, Gobbi de Oliveira Ricardo Cesar, Oliveira Renata Cristina
Department of Orthodontics, Ingá University Center UNINGÁ, Maringá, Brazil.
Pain Manag. 2021 Sep;11(5):583-593. doi: 10.2217/pmt-2020-0045. Epub 2021 May 13.
This prospective controlled clinical study aimed to evaluate the effect of botulinum toxin Type A (BTX-A) on pain control and quality of life (QoL) in patients with chronic myofascial pain. Patients with chronic myofascial pain were randomly divided into two groups (n = 20): counseling and self-care and Michigan-type occlusal splint (MOS) (CG-control group) or BTX-A injection (BTX-AG). The pain was evaluated with visual analogue scale and QoL with the oral health impact profile-14 (OHIP-14) questionnaire. In both groups, the pain was reduced, and QoL improved after 30 days. The results of social disability and handicap were better for patients treated with counseling and self-care and MOS. Minimally invasive strategies and BTX-A application improved QoL and alleviated myofascial pain.
这项前瞻性对照临床研究旨在评估A型肉毒杆菌毒素（BTX-A）对慢性肌筋膜疼痛患者疼痛控制和生活质量（QoL）的影响。慢性肌筋膜疼痛患者被随机分为两组（n = 20）：咨询与自我护理组以及密歇根型咬合板（MOS）组（CG-对照组）或BTX-A注射组（BTX-AG）。采用视觉模拟量表评估疼痛，并用口腔健康影响概况-14（OHIP-14）问卷评估生活质量。两组患者在30天后疼痛均减轻，生活质量均有所改善。咨询与自我护理及MOS治疗的患者在社会残疾和障碍方面的结果更好。微创策略和BTX-A的应用改善了生活质量并减轻了肌筋膜疼痛。
